Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • November 8th, 2013 • uniQure B.V. • Pharmaceutical preparations • New York
THIS Exclusive License Agreement (“Agreement”), effective as of 07 July 2008 (“Effective Date”), is entered into by and between St. Jude Children’s Research Hospital, Inc., a Tennessee not-for-profit corporation located at 262 Danny Thomas Place, Memphis, Tennessee 38105 (“ST. JUDE”) and Amsterdam Molecular Therapeutics B.V., a closed limited liability company organized and existing under the laws of the Netherlands, with registered offices at Meibergdreef 61, 1105 BA Amsterdam, the Netherlands, (each a “Party” and together the “Parties”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. NON-EXCLUSIVE LICENSE AGREEMENTNon-Exclusive License Agreement • November 8th, 2013 • uniQure B.V. • Pharmaceutical preparations • New York
This License Agreement (the “Agreement”), effective as of September 3, 2010 (the “Effective Date”), is by and between Asklêpios Biopharmaceutical, Inc., an entity organized and existing under the laws of the State of North Carolina, with its registered office located at 45 N. Chatham Parkway, Chapel Hill, NC 27517 (the “AskBio”), and Amsterdam Molecular Therapeutics (AMI) B.V., with offices located at Meibergdreef 61, 1100 DA Amsterdam, The Netherlands (“AMT”). AMT and AskBio may be hereinafter referred to individually as “Party” and jointly as “Parties”.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. License Agreement- Non- Exclusive (expresSF+® cells)License Agreement • November 8th, 2013 • uniQure B.V. • Pharmaceutical preparations • Connecticut
This License Agreement (the “Agreement”) is entered into and made effective the 22nd day of March, 2007, (the “Effective Date”) between PROTEIN SCIENCES CORPORATION, whose principal place of business is at 1000 Research Parkway, Meriden, CT 06512 USA (hereinafter referred to as “LICENSOR”) and AMSTERDAM MOLECULAR THERAPEUTICS whose principal place of business is at Meibergdreef 61, P.O. Box 22506, 1100 DA Amsterdam, The Netherlands, (hereinafter referred to as “LICENSEE”).
113 HARTWELL AVENUE LEXINGTON, MASSACHUSETTS LEASE SUMMARY SHEETLease Agreement • November 8th, 2013 • uniQure B.V. • Pharmaceutical preparations • Massachusetts
THIS INDENTURE OF LEASE (this “Lease”) is hereby made and entered into on the Execution Date by and between Landlord and Tenant.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AGREEMENT BETWEEN SALK INSTITUTE FOR BIOLOGICAL STUDIES AND AMSTERDAM MOLECULAR THERAPEUTICS BV RNA EXPORT...License Agreement • November 8th, 2013 • uniQure B.V. • Pharmaceutical preparations • California
Effective as of February 8, 2008 (“Effective Date”), THE SALK INSTITUTE FOR BIOLOGICAL STUDIES, a nonprofit public benefit corporation organized and existing under the laws of the State of California, U.S.A. (“Salk”), and Amsterdam Molecular Therapeutics BV, a corporation organized and existing under the laws of The Netherlands (“Licensee”), agree as follows:
ACCESSION AGREEMENT CLASS B SHAREHOLDERS AGREEMENTAccession Agreement • November 8th, 2013 • uniQure B.V. • Pharmaceutical preparations
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. DATED 16 JUNE 2006 ACADEMISCH MEDISCH CENTRUM - and - BEHEERSMAATSCHAPPIJ DIENSTVERLENING EN DEELNEMING AZUA B.V. - and...Confidentiality Agreement • November 8th, 2013 • uniQure B.V. • Pharmaceutical preparations
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AGREEMENTLicense Agreement • November 8th, 2013 • uniQure B.V. • Pharmaceutical preparations • Pennsylvania
THIS AGREEMENT (the “Agreement”) is made and is effective December 5, 2006, (the “Effective Date”) by and between Targeted Genetics Corporation, a corporation having a principal place of business at 1100 Olive Way, Suite 100, Seattle, Washington 98101 (“TGC”), and Amsterdam Molecular Therapeutics B.V. (“AMT”), a corporation having a principal place of business at Meibergdreef 61, 1100 DA Amsterdam, The Netherlands.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.License Agreement • November 8th, 2013 • uniQure B.V. • Pharmaceutical preparations
WHEREAS AVENTIS is the owner of the certain patents relating to the preparation and use of recombinant viruses in gene therapy.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. LICENSE AGREEMENT PreambleLicense Agreement • November 8th, 2013 • uniQure B.V. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”) effective as of November 30, 2010 (the “Effective Date”), is made by and between Amsterdam Molecular Therapeutics (AMT) B.V., a closed limited liability company with registered offices at Meibergdreef 61, 1100 DA Amsterdam, the Netherlands (“AMT’), and Amgen Inc., a Delaware corporation whose address is One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA (“Amgen”). AMT and Amgen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
DATED 19 APRIL 2012 Coöperatieve AAC LS U.A. Forbion Co-Investment Coöperatief U.A. Forbion Co-Investment II Coöperatief U.A. Coöperatieve Gilde Healthcare II U.A. and Stichting Administratiekantoor uniQure B.V. and uniQure B.V.Class B Shareholders Agreement • November 8th, 2013 • uniQure B.V. • Pharmaceutical preparations
The parties to this Agreement are hereinafter collectively referred to as the “Parties” and individually as a “Party”. Further details of the Parties are set out in SCHEDULE A (Parties). The Existing Investor I and the Existing Investor II are herinafter jointly referred to as the “Existing Investors”. The New Investor I and the New Investor II are hereinafter jointly referred to as the “New Investors”. The Existing Investors and the New Investors, together with any other holder from time to time of Ordinary Shares Class A in the capital of the Company, are hereinafter collectively referred to as the “Investors” and individually as an “Investor”.
UNIQURE LOAN AND SECURITY AGREEMENTLoan and Security Agreement • November 8th, 2013 • uniQure B.V. • Pharmaceutical preparations
THIS LOAN AND SECURITY AGREEMENT is made and dated as of June 13, 2013 and is entered into by and among (i) UNIQURE BIOPHARMA B.V., a private limited liability company incorporated and existing under the laws of the Netherlands, having its corporate seat at Amsterdam, the Netherlands and registered at the trade register of the Chamber of Commerce for Amsterdam under number 34275365 (“uniQure”), (ii) UNIQURE IP B.V., a private limited liability company incorporated and existing under the laws of the Netherlands, having its corporate seat at Amsterdam, the Netherlands and registered at the trade register of the Chamber of Commerce for Amsterdam under number 34275369 (“uniQure IP”), (iii) each of the subsidiaries of uniQure identified on the Schedule 1 hereto and the signature pages hereof (uniQure, uniQure IP and such subsidiaries are hereinafter collectively referred to as “Borrower”), (iv) UNIQURE B.V., a private limited liability company incorporated and existing under the laws of the
ACCESSION AGREEMENT CLASS A SHAREHOLDERS AGREEMENTAccession Agreement • November 8th, 2013 • uniQure B.V. • Pharmaceutical preparations
WARRANT AGREEMENT To subscribe for Warrant Shares in the share capital of UNIQURE B.V. Dated as of September 20, 2013 (the “Effective Date”)Warrant Agreement • November 8th, 2013 • uniQure B.V. • Pharmaceutical preparations
WHEREAS, uniQure Biopharma B.V., a limited liability company organized under the laws of The Netherlands, has entered into a Loan and Security Agreement on or about 11 June 2013 (the “Loan Agreement”) with Hercules Technology Growth Capital, Inc., a corporation organized under the laws of the State of Maryland, USA (the “Warrantholder”);
Execution version Subscription Agreement between Chiesi Farmaceutici S.p.A., as the Investor and uniQure B.V., as the Company SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT is made on 29 April 2013 BETWEEN: 1 Chiesi Farmaceutici S.p.A., a company...Subscription Agreement • November 8th, 2013 • uniQure B.V. • Pharmaceutical preparations
DATED 19 APRIL 2012 Coöperatieve AAC LS U.A. Forbion Co-Investment Coöperatief U.A. Forbion Co-Investment II Coöperatief U.A. Coöperatieve Gilde Healthcare II U.A. and uniQure B.V.Shareholder Agreements • November 8th, 2013 • uniQure B.V. • Pharmaceutical preparations
The parties to this Agreement are hereinafter collectively referred to as the “Parties” and individually as a “Party”. Further details of the Parties are set out in SCHEDULE A (Parties). The Existing Investor I and the Existing Investor II are hereinafter jointly referred to as the “Existing Investors”. The New Investor I and the New Investor II are hereinafter jointly referred to as the “New Investors”. The Existing Investors and the New Investors, together with any other holder from time to time of Ordinary Shares Class A in the capital of the Company, are hereinafter collectively referred to as the “Investors” and individually as an “Investor”.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. COMMERCIALIZATION AGREEMENTCommercialization Agreement • November 8th, 2013 • uniQure B.V. • Pharmaceutical preparations • England
This Commercialization Agreement (this “Agreement”) is entered into as of 29 April 2013 (the “Effective Date”), by and between uniQure Biopharma B.V., formerly known as Amsterdam Molecular Therapeutics (AMT) B.V., a Dutch corporation, with its offices at Meibergdreef 61, 1105 BA Amsterdam, The Netherlands (“uniQure”), and Chiesi Farmaceutici S.p.A., an Italian corporation, with its offices at Via Palermo, 26/A, 43122 Parma, Italy (“Chiesi”). uniQure and Chiesi are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. DATA LICENSE AGREEMENT between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and uniQure biopharma B.V. for AAV2.GDNF DataData License Agreement • November 8th, 2013 • uniQure B.V. • Pharmaceutical preparations • California
This license agreement (“Agreement”) is made effective this 12th day of June, 2012 (“Effective Date”), by and between The Regents of the University of California, a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200 (“The Regents”), acting through its Office of Technology Management, University of California, San Francisco, 185 Berry Street Suite 4603, San Francisco, California, 94107 (“UCSF”) and uniQure biopharma B.V. (uniQure) a Netherlands corporation, having a principal place of business at Meibergdreef 61, 1105 BA Amsterdam, the Netherlands (“Licensee”). The Regents and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
GRANT LETTERGrant Letter • November 8th, 2013 • uniQure B.V. • Pharmaceutical preparations
